

**OPTN/UNOS Histocompatibility Committee**  
**Meeting Summary**  
**February 9, 2016**  
**Conference Call**

**Dolly Tyan, PhD, D(ABHI), Chair**  
**Rober Bray, PhD, D(ABHI), Vice Chair**

*Discussions of the full committee on February 9, 2016 are summarized below and will be reflected in the committee's next report to the OPTN/UNOS Board of Directors. Meeting summaries and reports to the Board are available at <http://optn.transplant.hrsa.gov/> .*

### **Implemented Committee Projects**

#### **1. Data Monitoring of Implemented projects.**

In 2015, there were six Histocompatibility projects fully implemented. Three of those projects had an associated data monitoring plan to assure that the policies have the intended impact. The Committee reviewed the monitoring plans and asked the Research department to remove two components from the April, 2015 changes to HLA Equivalency Tables monitoring plan if Research can confirm that data are already being collected in the KAS data review.

The plan also included monitoring the frequency of reporting on the waiting list for unacceptable antigens that had changes in equivalencies. The Committee asked the research department to double-check the listed antigens to make sure they are the only ones that had equivalent antigens change.

The Committee then reviewed the data monitoring plan for the Expanding HLA Typing Requirements, which was implemented on January 21, 2016. The Committee asked if the data could include reports on the how often HLA-DQA1 and DPB1 were the reason for an unexpected positive crossmatch. The committee discussed the pitfalls of collecting this type of information, and suggested further discussion is warranted at future meetings. The Committee then requested that the Data monitoring plan be distributed following the meeting for everyone to review before it is finalized and approved.

### **Review of Public Comment Proposals**

The Chair of the Kidney Committee made two presentations to the Histocompatibility Committee of their proposals currently out for public comment:

#### **2. Simultaneous Liver-Kidney Allocation**

Simultaneous Liver-Kidney Allocation. The Histocompatibility Committee had no questions or comments following the presentation.

#### **3. KAS Clarifications and Cleanup**

KAS Clarifications and Cleanups. This proposal specifically relates to changing policy to discontinue OPO capping of offers to highly sensitized and zero mismatch candidates before exhausting the match run. Following the presentation, the Histocompatibility Committee had no questions or comments for the presenter. The Committee was urged by their Chair to make comments to these proposals on the OPTN Public Comment website.

## **Upcoming Meetings**

- Tuesday March 8, 2016 from 12pm – 1pm EST via GoToTraining and Teleconference.